These reports are authored by GW Regulatory Studies Center scholars Bridget C.E. Dooling and Laura E. Stanley with support from The Pew Charitable Trusts.
Telehealth, COVID-19, and the Opioid Crisis
Published February 23, 2021
Do federal regulatory agencies have the authority to extend flexibilities for the treatment of opioid use disorder beyond the COVID-19 pandemic?
Bridget C.E. Dooling and Laura E. Stanley provide details on the rulemaking background for medical practitioners and policy makers, and layout their findings on what the Drug Enforcement Administration and Substance Abuse & Mental Health Services Administration can do going forward.
Coming April 2021
"The coronavirus crisis has upended American life, and fresh ideas are needed for dealing with the problems it’s creating. Here is a collection of smart solutions." - Washington Post
Laura Stanley's essay was featured as one of the Washington Post's smart ideas to reduce the impact of the coronavirus on our lives.
Read Laura's full essay: Bring back the methadone vans
Laura Stanley joins GW Regulatory Studies Center communications and outreach manager Bryce Chinault to discuss related regulations at the Drug Enforcement Administration.
The Trump administration made a last-minute attempt to provide flexibilities for prescribing buprenorphine to treat opioid use disorder. The Biden administration changed course and decided not to publish the associated guidelines due to legal and policy concerns. Although HHS appears to have the legal authority to provide exemptions from buprenorphine requirements, taking time to ensure flexibilities are legally defensible will promote the uptake of the policies in the long term.
Read Laura Stanley's full Commentary: A Last-Minute Attempt to Partially X the X Waiver